Molecular prognostic markers in pancreatic cancer: A systematic review

European Journal of Cancer

Volumn 41, Issue 15, 2005, Pages 2213-2236

  Garcea, G ^a   Neal, C P ^a   Pattenden, C J ^b   Steward, W P ^a   Berry, D P ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; Pancreatic cancer; Prognosis; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CATHEPSIN; CYCLIN D1; CYTOKINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR; GENE PRODUCT; HEPARANASE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HERMES ANTIGEN; INTEGRIN; INTERLEUKIN 8; K RAS PROTEIN; LAMININ; MATRIX METALLOPROTEINASE; MOLECULAR MARKER; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN;

ACCURACY; ANGIOGENESIS; APOPTOSIS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CORRELATION ANALYSIS; DISEASE MARKER; DNA MICROARRAY; DRUG EFFICACY; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; ONCOGENE; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVIEW; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 26244452319     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.04.044     Document Type: Article

References (170)

1. F.A. Real A 'catastrophic hypothesis' for pancreas cancer progression Gastroenterology 124 2003 1958 1964
2. J.P. Duffy, G. Eibl, and H.A. Reber Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer Mol Cancer 2 2003 12
3. B.A. Miller, L.N. Koloenel, and L. Berstein Racial/ethnic patterns of cancer in the United States 1998-92 NIH publication No. 96-4104 1996 National Cancer Institute Bethseda, MD
4. J.E. Niederhuber, M.F. Brennan, and H.R. Menck The National Cancer Data Base report on pancreatic cancer Cancer 76 1995 1671 1677
5. E. Solcia, C. Capella, and G. Kloppel Tumours of the pancreas 1995 Universities Associated for Research and Education in Pathology Washington, DC
6. T.P. Wade, I.A. Halaby, and D.R. Stapleton Population based analysis of treatment of pancreatic cancer and Whipple resection: Department of Defence Hospitals 1989-1994 Surgery 120 1996 680 687
7. P.S. Moore, S. Orlandini, and G. Zamboni Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis Br J Cancer 84 2001 253 262
8. E. Rozenblum, M. Schutte, and M. Goggins Tumour-suppressive pathways in pancreatic carcinoma Cancer Res 57 1997 1731 1734
9. J.A. Hickman Apoptosis induced by anticancer drugs Cancer Metast Rev 11 1992 121 139
10. T. Naka, M. Kobayashi, and K. Ashida Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer Int J Oncol 12 5 1998 1111 1116
11. A. Kawesha, P. Ghaneh, and A. Andren-Sandberg K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma Int J Cancer 89 6 2000 469 474
12. M. Dong, Y. Nio, and K. Yamasawa p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer J Surg Oncol 82 2003 111 120
13. Y. Nio, M. Dong, and C. Iguchi Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy J Surg Oncol 76 2001 188 196
14. Y.X. Hu, H. Watanabe, and K. Ohtsubo Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma Br J Cancer 80 1999 1075 1079
15. J. Lundin, S. Nordling, and K. von Boguslawsky Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer Oncology 53 2 1996 104 111
16. Y. Nio, M. Dong, and K. Uegaki p53 expression affects the efficacy of adjuvant chemotherapy after resection of invasive ductal carcinoma of the pancreas Anticancer Res 18 5B 1998 3773 3779
17. Y. Nio, M. Dong, and K. Uegaki Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas Pancreas 18 2 1999 117 126
18. M. Dong, Y. Nio, and K. Tamura Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese and Western patients Cancer Epidemiol Biomarkers Prev 9 2000 279 284
19. S.T. Dergham, M.C. Dugan, and R. Kucway Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma Int J Pancreatol 21 2 1997 127 143
20. M. Yokoyama, Y. Yamanaka, and H. Friess p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness Anticancer Res 14 6B 1994 2477 2483
21. S. Nakamori, K. Yashima, and Y. Murakami Association of p53 gene mutations with short survival in pancreatic adenocarcinoma Jpn J Cancer Res 86 2 1995 174 181
22. S.Y. Zhang, B. Ruggeri, and P. Agarwal Immunohistochemical analysis of p53 expression in human pancreatic carcinomas Arch Pathol Lab Med 118 2 1994 150 154
23. J.A. DiGiuseppe, R.H. Hruban, and S.N. Goodman Overexpression of p53 protein in adenocarcinoma of the pancreas Am J Clin Pathol 101 1994 684 688
24. B.A. Ruggeri, L. Huang, and D. Berger Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions Cancer 79 4 1997 700 716
25. A.V. Biankin, A.L. Morey, and C. Lee DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma J Clin Oncol 20 2002 4531 4542
26. D. Campani, U. Boggi, and D. Cecchetti p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer Pancreas 19 1999 26 32
27. G. Ohshio, H. Suwa, and T. Immamura An immunohistochemical study of blc-2 and p53 protein expression in pancreatic carcinomas Scand J Gastroenterol b33 1998 535 539
28. K. Makinen, T. Hakala, and P. Lipponen Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma Anticancer Res 18 1998 615 618
29. H. Mueller, and U. Eppenberger The dual role of mutant p53 protein in chemosensitivity of human cancers Anticancer Res 16 6B 1996 3845 3848
30. R.D. Petty, I.A. Cree, and L.A. Sutherland Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity Biochem Biophys Res Commun 199 1994 264 270
31. S. Fan, M.L. Smith, and D.J. Rivet Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline Cancer Res 55 1995 1649 1654
32. M. Serrano, G.J. Hannon, and D. Beach A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 Nature 366 1993 704 707
33. K. Ohtsubo, H. Watanabe, and Y. Yamaguchi Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters J Gastroenterol 38 7 2003 663 671
34. B. Gerdes, A. Ramaswamy, and A. Ziegler p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb Ann Surg 235 1 2002 51 59
35. Y.X. Hu, H. Watanabe, and K. Ohtsubo Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma Clin Cancer Res 3 9 1997 1473 1477
36. S. Sasaki, H. Yamamoto, and H. Kaneto Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas Oncol Rep 10 1 2003 21 25
37. R.H. Weiss p21Waf1/Cip1 as a therapeutic target in breast and other cancers Cancer Cell 4 6 2003 425 429
38. Y. Xiong, G.J. Hannon, and H. Zhang p21 is a universal inhibitor of cyclin kinases Nature 366 6456 1993 701 704
39. Y. Hashimoto, Y. Nio, and S. Sumi Correlation between TGF-beta 1 and p21 (WAFI/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas Pancreas 22 2001 341 371
40. M.M. Song, Y. Nio, and M. Dong Comparison of K-ras mutation at codon 12 and p21 expression in pancreatic cancer between Japanese and Chinese patients J Surgical Oncol 75 2000 176 185
41. S.A. Ahrendt, H.M. Brown, and R.A. Komorowski p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer Surgery 128 2000 520 530
42. D. Coppola, L. Lu, and J.P. Frehauf Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta 1 protein expression predicts longer survival Am J Clin Pathol 110 1998 16 23
43. M.M. Song, Y. Nio, and Y. Sato Clinicopathological significance of K-ras point mutation and expression in benign and malignant exocrine tumours of the human pancreas Int J Pancreatology 20 1996 85 93
44. K. Yamaguchi, and M. Enjoji Carcinoma of the pancreas: a clinicopathologic study of 96 cases with immunohistological observations Jap J Clin Oncol 19 1989 14 22
45. S.T. Dergham, M.C. Dugan, and U.S. Joshi The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma Cancer 80 3 1997 372 381
46. S.A. Hahn, M. Schutte, and A.T. Hoque DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1 Science 271 5247 1996 350 353
47. Z.H. Tang, S.Q. Zou, and Y.H. Hao The relationship between loss expression of DPC4/Smad4 gene and carcinogenesis of pancreatobiliary carcinoma Hepatobiliary Pancreat Dis Int 1 4 2002 624 629
48. F. Liu SMAD4/DPC4 and pancreatic cancer survival Clin Cancer Res 7 2001 3853 3856
49. I. Schwarte-Waldhoff, and W. Schmiegel Smad4 transcriptional pathways and angiogenesis Int J Gastrointest Cancer 31 1-3 2002 47 59
50. Z. Hua, Y.C. Zhang, X.M. Hu, and Z.G. Jia Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma World J Gastroenterol 9 2003 2764 2767
51. M. Tascilar, H.G. Skinner, and C. Rosty The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma Clin Cancer Res 7 2001 4115 41121
52. C. Lu, S. Morita, and T. Ishibashi Loss of p27-kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma Cancer 85 1999 1250 1260
53. A. Juuti, S. Nordling, and J. Louhimo Loss of p27 expression is associated with poor prognosis in stage I-II pancreatic cancer Oncology 65 2003 371 377
54. R.M. Feakins, and A.J. Ghaffar p27 Kip expression is reduced in pancreatic carcinoma but of limited prognostic value Hum Pathol 34 2003 385 390
55. K. Grunewald, J. Lyons, and A. Frohlich High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas Int J Cancer 43 1989 1037 1041
56. V. Smits, A. Boot, and A. Smit K-ras mutations occur very frequently in pancreatic adenocarcinomas Nucl Acids Res 16 1988 7773 7782
57. C. Almoguera, and K.F. Shibatad Most human carcinomas of the exocrine pancreas contain mutant K-ras genes Cell 53 1988 549 553
58. P. Ghaneh, A. Kawesha, and J.D. Evans Molecular prognostic markers in pancreatic cancer J Hepatobiliary Pancreat Surg 9 2002 1 11
59. A. Castells, P. Puig, and J. Mora K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance J Clin Oncol 17 1999 578 584
60. D.C. Allison, S. Piantadosi, and R.H. Hruban DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma J Surg Oncol 6 1998 151 159
61. M. Kitago, M. Ueda, and K. Airura Comparison of K-ras mutation distributions in intraductal papillary mucinous tumours and ductal adenocarcinoma of the pancreas Int J Cancer 10 2004 177 182
62. K. Motojima, T. Urano, and Y. Nagata Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumour stage in human pancreatic carcinoma Am J Gastroenterol 86 1991 1784 1788
63. S.D. Finkelstein, R.M. Przygodzki, and V.E. Pricolo K-ras-2 topographic genotyping of pancreatic adenocarcinoma Arch Surg 129 1994 367 372
64. R.H. Hruban, A.D. Van Mansfield, and G. Offerhaus K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant enriched chain reaction analysis and allele specific oligonucleotide hybridization Am J Pathol 143 1993 545 554
65. M. Span, P.T. Moerkerk, and A.F. De Goeij A detailed analysis of K-ras mutations in relation to tumour progression and survival in colorectal cancer patients Int J Cancer 69 1996 241 245
66. O. Tetsu, and F. McCormick Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells Nature 398 1999 422 426
67. S. Gansauge, F. Gansuage, and M. Ramadani Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis Cancer Res 57 1997 1634 1637
68. F. Gansauge, S. Gansauge, and E. Schmidt Prognostic significance of molecular alterations in human pancreatic carcinoma: an immunological study Langebecks Arch Surg 383 1998 152 155
69. Q. Qiao, M. Ramadani, and S. Gansauge Reduced membranous and ectopic cytoplasmic expression of beta-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer Int J Cancer 95 2001 194 197
70. Y.J. Li, and X.R. Ji Relationship between the expression of beta-catenin, cyclin D1 and myc and the occurrence and biological behaviour of pancreatic cancer Zhonghua Bing Li Xue Za Zhi 32 2003 238 241
71. M. Kornmann, T. Ishiwata, and J. Itakura Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival Oncology 55 4 1998 363 369
72. A. Gross, T.J. McDonnell, and S.J. Korsmeyer BCL-2 family members and the mitochondria in apoptosis Genes Dev 13 1999 1899 1911
73. F.R. Greten, C.K. Weber, and T.F. Greten Stat3 and NF-kB activation prevents apoptosis in pancreatic carcinogenesis Gastroenterology 123 2002 2052 2063
74. F.A. Sinicrope, D.B. Evans, and S.D. Leach bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome Clin Cancer Res 2 12 1996 2015 2022
75. C.Y. Sun, B.L. Wang, and C.Q. Hu Expression of the bcl-2 gene and its significance in human pancreatic cancer Hepatobiliary Pancreatic Dis Int 1 2002 306 308
76. Y. Nio, C. Iguchi, and K. Yamasawa Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas Pancreas 22 2001 230 239
77. J.D. Evans, P.A. Cornford, and A. Dodson Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas Pancreatology 1 2001 254 262
78. D. Campani, I. Esposito, and U. Boggi Bcl-2 expression in pancreas development and pancreatic cancer progression J Pathol 194 2001 444 450
79. H. Friess, Z. Lu, and H.U. Graber bax, but not bcl-2, influences the prognosis of human pancreatic cancer Gut 43 1998 414 421
80. H. Friess, Z. Lu, and A. Andren-Sandberg Moderate activation of the apoptosis inhibitor bcl-xL worsens prognosis in pancreatic cancer Ann Surg 228 1998 78 787
81. K. Kami, R. Doi, and M. Koizuma Survivin expression is a prognostic marker in pancreatic cancer patients Surgery 136 2004 443 448
82. K. Satoh, K. Kaneko, and M. Hirota Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumours Cancer 92 2001 271 278
83. A.I. Sarela, C.S. Verbeke, and J. Ransdale Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma Br J Cancer 86 2002 886 892
84. J.G. Qiao, Y.Q. Zhang, and Y.C. Yin Expression of survivin in pancreatic cancer and its correlation to expression of Bcl-2 World J Gastroenterol 10 2004 2759 2761
85. K. Asanuma, R. Moriai, and T. Yajima Survivin as a radioresistance factor in pancreatic cancer Jap J Cancer Res 91 2000 1204 1209
86. F. Ozawa, H. Friess, and A. Tempia-Caliera Growth factors and their receptors in pancreatic cancer Teratogen, Carcinogen Mutagen 21 2001 27 44
87. J. Massague, S. Cheifetz, and M. Laiho Transforming growth factor-beta Cancer Surv 12 1992 81 103
88. J. Massague The transforming growth factor-beta family Ann Rev Cell Biol 6 1990 597 641
89. M. Wagner, J. Kleeff, and H. Friess Enhanced expression of the type II transforming growth factor beta receptor is associated with decreased survival in human pancreatic cancer Pancreas 19 1999 370 376
90. H. Friess, Y. Yamanaka, and M. Buchler Enhanced expression of transforming growth factor beta isoform-2 in pancreatic cancer correlates with decreased survival Gastroenterology 105 1993 1846 1856
91. R. Sasada, Y. Ono, and Y. Taniyama Cloning and expression of cDNA encoding human betacellulin, a new member of the EGF family Biochem Biophys Res Commun 190 1993 1173 1179
92. R. Derynck The physiology of transforming growth factor alpha Semin Cancer Biol 58 1992 27 52
93. K.M. Davis-Fleischer, and G.E. Besner Structure and function of heparin-binding EGF-like growth factor (HB-EGF) Frontiers Biosci 3 1998 288 299
94. K.L. Carraway, C.K. Weber, and M.J. Unger Neuroregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases Nature 387 1997 512 516
95. D.J. Laurence, and B.A. Gusterton The epidermal growth factor: a review of structural and functional relationships in the normal organism and in cancer cells Tumour Biol 11 1990 229 261
96. M. Dong, Y. Nio, and K.-J. Guo Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer Anticancer Res 18 1998 4613 4619
97. Y. Ito, S. Higashiyama, and T. Takeda Expression of heparin-binding epidermal growth factor -like growth factor receptor in pancreatic adenocarcinoma Int J Pancreatol 29 2001 47 52
98. K. Uegaki, Y. Nio, and S. Inoue Clinicopathological significance of epidermal growth factor and receptor in human pancreatic cancer Anticancer Res 17 1997 3841 3847
99. H. Friess, Y. Yamanaka, and M.S. Kobrin Enhanced erB-3 expression in human pancreatic cancer correlates with tumour progression Clin Cancer Res 11 1995 1413 1420
100. Y. Yamanaka The immunohistochemical expressions of epidermal growth factor, epidermal growth factor receptors and c-erbB2 oncoprotein in human pancreatic cancer Nippon Ika Daigaku Zasshi 59 1992 51 61
101. Y. Yamanaka, H. Friess, and M.S. Kobrin Co-expression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumour aggressiveness Anticancer Res 13 1993 565 570
102. M. Ueda, S. Ogata, and H. Tsuda The correlation between cytoplasmic overexpression of epidermal growth factor and tumour aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma Pancreas 29 2004 1 8
103. D. Tamiolakis, I. Venizelos, and C. Simopoulos Correlation of immunohistochemically detected HER-2/neu (erbB-2) with histological stage and perineural invasion in pancreatic cancer Hepatogastroenterology 51 2004 334 337
104. K. Tobita, H. Kijima, and S. Dowaki Epidermal growth factor expression in human pancreatic carcinoma: significance for liver metastasis Int J Mol Med 11 2003 305 309
105. H. Zhang, and S.Z. Yuan Expression of c-erbB2 oncogene protein, epidermal growth factor receptor and TGF-beta1 in human pancreatic ductal adenocarcinoma Hepatobiliary Pancreatic Dis Int 1 2002 620 623
106. V. Koka, A. Potti, and M. Koch Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression of pancreatic carcinoma Anticancer Res 22 2002 1593 1597
107. A. Thybusch-Bernhardt, S. Beckmann, and H. Juhl Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumour stage Int J Surg Invest 2 2001 393 400
108. H. Safran, M. Steinhoff, and S. Mangray Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma Am J Clin Oncol 24 2001 496 499
109. J. Novotny, L. Petruzelka, and J. Vedralova Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients Neoplasma 48 2001 188 191
110. H.U. Graber, H. Friess, and B. Kaufmann ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer Int J Cancer 84 1999 24 27
111. M.C. Dugan, S.T. Dergham, and R. Kucway HER-2/neu expression in pancreatic adenocarcinoma: relationship to tumour differentiation and survival Pancreas 14 1997 229 236
112. N. Okada, G. Ohshio, and K. Yamaki Elevated serum c-erbB-2 protein levels in patients with pancreatic cancer: correlation to metastasis and shorter survival Oncology 52 5 1995 392 396
113. S. Lei, H.E. Appert, and B. Nakata Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival Int J Pancreatol 17 1995 15 21
114. H. Kuniyasu, L.M. Ellis, and D.B. Evans Relative expression of E-cadherin and type IV collegenase genes predicts disease outcome in patients with resectable pancreatic carcinoma Clin Cancer Res 5 1999 25 33
115. P. August, S. Javerzat, and A. Bikfalvi Regulation of vascular development by fibroblast growth factors Cell Tissue Res 8 2003 204 210
116. R. Montesano, J.D. Vassalli, and A. Baird Basic fibroblast growth factor induces angiogenesis in vitro Acad Sci USA 83 1986 7297 7301
117. T. Ohta, H. Yammamoto, and M. Numata Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas Br J Cancer 72 1995 824 831
118. Y. Yamanaka, H. Friess, and M. Buchler Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumour stage Cancer Res 53 1993 5289 5296
119. L. Jones, P. Ghaneh, and M. Humphreys The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer Ann NY Acad Sci 30 1999 288 307
120. S.R. Harvey, T.C. Hurd, and G. Markus Evaluation of urinary plasminogen activator, its receptor matrix metalloproteinase-9 and von Willebrand factor in pancreatic cancer Clin Cancer Res 15 2003 4935 4943
121. H. Nakamura, S. Horita, and N. Senmaru Association of matrilysin expression with progression and poor prognosis in human pancreatic adenocarcinoma Oncol Rep 9 2002 751 755
122. H. Yammamoto, F. Itah, and S. Iku Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression J Clin Oncol 19 2001 1118 1127
123. M. Maata, Y. Soini, and A. Liakka Differential expression of matrix metalloproteinase (MMP)-2 and 9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumour progression and clinical prognosis Clin Cancer Res 6 2000 2726 2734
124. Y.L. Gong, G.M. Xu, and W.D. Huang Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer J Surg Oncol 73 2000 95 99
125. T. Ito, M. Ito, and J. Shiozawa Expression of MMP-1 in human pancreatic carcinoma: relationship with prognostic factors Mod Pathol 12 1999 669 674
126. T. Koshiba, R. Hosotani, and M. Wada Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma Cancer 82 1998 642 650
127. D. Cantero, H. Friess, and J. Deflorin Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic cancer Br J Cancer 75 1997 388 395
128. J.A. Joyce, A. Baruch, and K. Chehade Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumourigenesis Cancer Cell 5 2004 443 453
129. M. Niedergethmann, R. Hildenbrand, and G. Wolf Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection Int J Pancreatol 28 2000 31 39
130. F.M. Tumminello, G. Leto, and G. Pizzolanti Cathepsin D, B and L circulating levels as prognostic markers of malignant progression Anticancer Res 16 1996 2315 2319
131. J. Rohloff, J. Zinke, and K. Schoppmeyer Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma Br J Cancer 22 2002 1270 1275
132. E.K. Kim, S. Xu, and E.F. Hollinger Human heparanase-1 gene expression in pancreatic cancer J Gastrointestinal Surg 6 2002 167 172
133. A. Koliopanos, H. Friess, and J. Kleeff Heparanase expression in primary and metastatic pancreatic cancer Cancer Res 61 2001 4655 4659
134. K. Takahashi, T. Hasebe, and T. Oda Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastases and poor prognosis in patients with pancreatic ductal adenocarcinoma Cancer 94 2002 1894 1901
135. T. Gotoda, Y. Matsumara, and H. Kondo Expression of CD44 variants and its association with survival in pancreatic cancer Jap J Cancer Res 89 1998 1033 1040
136. F. Gansuage, S. Gansuage, and R. Bettina Low serum levels of soluble CD44 variant6 are significantly associated with poor prognosis in patients with pancreatic carcinoma Cancer 80 1997 1733 1739
137. R. Tomaszewska, K. Nowak, and J. Stachura CD44 isoforms expression in intraductal and invasive pancreatic cancer and its correlation to p53 gene mutations Polish J Pathol 50 1999 145 153
138. T.C. Bottger, H. Maschek, and W. Gottwald Expression of CD44 and isoforms v4, v5, v6, v7, v10: new prognostic parameters in ductal pancreatic carcinoma Chirugie 69 1998 1089 1092
139. R. Hosotani, M. Kawaguchi, and T. Masui Expression if integrin alphaVbeta3 in pancreatic carcinoma: link to MMP-2 activation and lymph node metastases Pancreas 25 2002 30 35
140. H. Sawai, H. Funahashi, and Y. Matsuo Expression and prognostic roles of integrins and interleukin receptor type I in patients with ductal adenocarcinoma of the pancreas Digestive Dis Sci 48 2003 1241 1250
141. T.C. Bottger, H. Maschek, and M. Lobo Prognostic value of immunohistochemical expression of beta-integrin in pancreatic carcinoma Oncology 56 1999 308 313
142. H. Doucas, G. Garcea, and M. Manson Changes in the Wnt signalling pathway in gastrointestinal cancers and their prognostic significance Eur J Cancer 41 2005 365 379
143. K. Julkunen, K. Makinen, and V. Karja Alpha, beta and chi-catenin expression in human pancreatic cancer Anticancer Res 23 2003 5043 5047
144. A.M. Lowy, C. Fenoglio-Preiser, and O.J. Kim Dysregulation of beta-catenin expression correlates with tumour differentiation in pancreatic duct adenocarcinoma Ann Surg Oncol 10 2003 284 290
145. Y.E. Joo, J.S. Rew, and C.S. Park Expression of E-cadherin, alpha and beta-catenins in patients with pancreatic adenocarcinoma Pancreatology 2 2002 129 137
146. A.J. Karayiannakis, K.N. Syrigos, and A. Polychroncdis Expression patterns of alpha-, beta- and gamma-catenin in pancreatic cancer: correlation with E-cadherin expression, pathological features and prognosis Anticancer Res 21 2001 4127 4134
147. J. Folkman How is blood vessel growth regulated in normal and neoplastic tissue? GHA. Clowes memorial award lecture Cancer Res 46 1986 467 473
148. J. Folkman What is the evidence that tumours are angiogenesis dependent? Natl Cancer Inst 82 1990 4 6
149. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Med 1 1995 27 31
150. E. Tischer, R. Mitchell, and T. Hartman The human gene for vascular endothelial growth factor. Multiple proteins are encoded through alternative exon splicing J Biol Chem 266 1991 11947 11954
151. K. Kuwahara, T. Sasaki, and Y. Kuwada Expression of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathological parameters and patient survival Pancreas 26 2003 344 349
152. A.J. Karayiannakis, H. Bolanaki, and K.N. Syrigos Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis Cancer Letts 194 2003 119 124
153. P. Buchler, H.A. Reber, and M.W. Buchler VEGF-RII influences the prognosis of pancreatic cancer Ann Surg 236 2002 738 749
154. M. Niedergethmann, R. Hildenbrand, and B. Wostbrock High expression of vascular endothelial growth factor predicting early recurrence and poor prognosis after curative resection of ductal adenocarcinoma of the pancreas Pancreas 25 2002 122 129
155. S. Fujioka, K. Yoshida, and S. Yanagisawa Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stroma cells and intratumoural microvessel density as independent predictors of overall and relapse-free survival Cancer 92 2001 1788 1797
156. Y. Seo, H. Baba, and T. Fukuda High expression of vascular endothelial growth factor is associated with liver metastasis and poor prognosis for patients with ductal adenocarcinoma Cancer 88 2000 2239 2245
157. N. Ikeda, M. Adachi, and T. Taki Prognostic significance of angiogenesis in human pancreatic cancer Br J Cancer 79 1999 1553 1563
158. K. Fujimoto, R. Hosotani, and M. Wada Expression of two angiogenic factors, vascular endothelial cell growth factor and platelet derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis Eur J Cancer 34 1998 1439 1447
159. L.M. Ellis, K. Takahashi, and C.J. Fenoglio Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma Eur J Cancer 34 1998 337 340
160. J. Itakura, T. Ishiwata, and H. Friess Enhanced expression of vascular endothelial growth factor in pancreatic cancer correlates with local disease progression Clin Cancer Res 8 1997 1309 1316
161. Y. Minari, Y. Nio, and N. Hirahara Heterogeneic distribution of thymidine phosphorylase between primary tumours and metastatic lesions of human pancreatic carcinoma. implications for the efficacy of chemotherapy with it or its derivatives Cancer Chemother Pharmacol 47 2001 415 422
162. S. Takao, Y. Takebasyshai, and X. Che Expression of thymidine phosphorylase is associated with poor prognosis in patients with ductal adenocarcinoma of the pancreas Clin Cancer Res 4 1998 1619 1624
163. N.L. Baenzinger, G.N. Brodie, and P.W. Majerus Isolation and properties of a thrombin-sensitive protein of human platelets J Biol Chem 247 1972 2723 2731
164. U. Kasper, M. Ebert, and P. Malfertheiner Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density Virchows Arch 438 2001 116 120
165. X. Qian, V.L. Rothman, and R.F. Nicosia Expression of thrombosponind-1 in human pancreatic adenocarcinomas: Role of matrix metalloproteinase-9 production Pathol Oncol Res 7 2001 251 259
166. K. Tobita, H. Kijima, and S. Dowaki Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma Int J Oncol 21 2002 1189 1195
167. S. Shimoyama, F. Gansuage, and S. Gansauge Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness Cancer Res 56 2003 2703 2706
168. A. Valerio, D. Basso, and S. Mazza Serum protein profiles of patients with pancreatic cancer and chronic pancreatitis: searching for a diagnostic protein pattern Rapid Commun Mass Spectrom 15 2001 2420 2425
169. C. Rosty, and M. Goggins Identification of differentially expressed proteins in pancreatic cancer using a global proteomic approach Methods Mol Med 103 2003 189 198
170. S. Battacharyya, E.R. Siegel, and G.M. Peterson Diagnosis of pancreatic cancer using serum proteomic profiling Neoplasia 5 2004 674 686